EZH2 and embryonal rhabdomyosarcoma: To translate the results obtained by gene inhibition of EZH2, in the study reviewed previously [62], into a future potential clinical approach for the treatment of aggressive embryonic rhabdomyosarcoma, the feasibility of pharmacological inhibition of EZH2 in RD cells was evaluated.